A Phase 1 Study Evaluating the Safety and
Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory
Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Principal Investigator:

William G. Wierda

Treatment Agent:

ABT-199

Study Status:

Closed

Study Description:

The goal of this clinical research study is to find the highest tolerable dose
of ABT-199 that can be given patients with relapsed or refractory CLL, NHL, or
SLL. The safety of this drug will also be studied.

ABT-199 is designed to block a critical protein that the leukemia cells need to
survive, which may kill cancer cells and shrink tumors. This is the first study
using ABT-199 in humans.